| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22027 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Is indicated in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. |
| Rapid review commissioned |
27/04/2022 |
| Rapid review completed |
26/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
| Pre-submission consultation with Applicant |
30/08/2022 |
| Full submission received from Applicant |
16/03/2023 |
